← United States · Coverage record
US · SEC FORM 4
Vanda Pharmaceuticals Inc.
VNDA · Nasdaq · CIK 0001347178 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
9 Form 4 transaction lines observed in the same window
0 sales · 9 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-08-07 · Polymeropoulos Mihael Hristos.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 7,831,971
- Previous report
- 8,495,290
- Avg daily volume
- 1,213,899
- Days to cover
- 6.5
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-08-07 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 4.15 | USD 41,500 | SEC filing ↗ |
| 2025-05-21 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 4.40 | USD 43,995 | SEC filing ↗ |
| 2025-05-16 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 20,000 | USD 4.22 | USD 84,400 | SEC filing ↗ |
| 2025-03-06 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 5.01 | USD 50,150 | SEC filing ↗ |
| 2025-03-05 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 5.02 | USD 50,200 | SEC filing ↗ |
| 2025-03-03 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 4.71 | USD 47,100 | SEC filing ↗ |
| 2025-02-28 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 4.76 | USD 47,600 | SEC filing ↗ |
| 2025-02-27 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 4.76 | USD 47,600 | SEC filing ↗ |
| 2025-02-26 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 4.76 | USD 47,650 | SEC filing ↗ |
| 2025-02-25 | Polymeropoulos Mihael Hristos | Purchase (P) | Common Stock | 10,000 | USD 4.46 | USD 44,600 | SEC filing ↗ |
| 2025-02-21 | Moran Kevin Patrick | Purchase (P) | Common Stock | 2,000 | USD 4.39 | USD 8,780 | SEC filing ↗ |
Form 4 evidence
20 transaction lines in the latest 365-day window; 221 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Ward Anne Sempowski | Award / grant (A) | Common Stock | 41,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-04 | Mitchell Stephen Ray | Award / grant (A) | Common Stock | 41,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-04 | McGuire Daniel Patrick | Award / grant (A) | Common Stock | 80,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Show recent Form 4 evidence (20 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Ward Anne Sempowski | Award / grant (A) | Common Stock | 41,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-04 | Mitchell Stephen Ray | Award / grant (A) | Common Stock | 41,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-04 | McGuire Daniel Patrick | Award / grant (A) | Common Stock | 80,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-04 | Honore Tage | Award / grant (A) | Common Stock | 41,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-04 | Duncan Charles Cliff | Award / grant (A) | Common Stock | 41,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-04 | DUGAN RICHARD W | Award / grant (A) | Common Stock | 41,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-04 | Chrousos Phaedra | Award / grant (A) | Common Stock | 41,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-18 | Mitchell Stephen Ray | Gift (G) | Common Stock | 25,836 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-22 | Duncan Charles Cliff | Award / grant (A) | Common Stock | 57,101 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-02 | Williams Timothy | Sale (S) | Common Stock | 42,434 | USD 8.27 | USD 350,929 | SEC filing ↗ |
| 2026-03-02 | Wijkstrom Joakim | Sale (S) | Common Stock | 30,800 | USD 8.27 | USD 254,716 | SEC filing ↗ |
| 2026-03-02 | Polymeropoulos Mihael Hristos | Sale (S) | Common Stock | 156,235 | USD 8.17 | USD 1,276,440 | SEC filing ↗ |
| 2026-03-02 | Moran Kevin Patrick | Sale (S) | Common Stock | 42,442 | USD 8.27 | USD 350,995 | SEC filing ↗ |
| 2026-03-02 | Birznieks Gunther | Sale (S) | Common Stock | 42,431 | USD 8.27 | USD 350,904 | SEC filing ↗ |
| 2026-02-23 | Honore Tage | Sale (S) | Common Stock | 30,000 | USD 8.03 | USD 240,900 | SEC filing ↗ |
| 2026-02-18 | Williams Timothy | Award / grant (A) | Common Stock | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-18 | Wijkstrom Joakim | Award / grant (A) | Common Stock | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-18 | Polymeropoulos Mihael Hristos | Award / grant (A) | Common Stock | 525,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-18 | Moran Kevin Patrick | Award / grant (A) | Common Stock | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-18 | Birznieks Gunther | Award / grant (A) | Common Stock | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | VNDA |
| CIK | 0001347178 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 221 transaction lines from 2020-01-02 to 2026-06-04 15 P purchase lines · 103 S sale lines · 103 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.